A Phase 3 interventional study of Eloralintide and Placebo in Osteoarthritis and Overweight or Obesity, sponsored by Eli Lilly and Company. Recruiting at 147 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.
Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 31st largest by planned enrollment of the 832 interventional ones that give a count, is one of 36 that started in 2026, is one of 128 in phase 3, reaches primary completion later than 122 of the 174 other live ones, and was the 1,009th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
Columbia University · Sites in United States
Ages 18+
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,029 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 155 · Phase 3 143 · Phase 4 74
First in 1977; this study’s year is marked. 36 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 900 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 100 across the 832 interventional studies, 114 across the 188 observational. Of the 759 that completed or were terminated, 338 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
473 of 1,029 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 8 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
60 of the studies in Osteoarthritis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06269705Phase 3Pacira Pharmaceuticals, IncZILRETTA in Subjects With Shoulder Osteoarthritis | 2026-12 |
| NCT05992883Phase 3Mayo ClinicNSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis | 2026-12-31 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT06003101Phase 3Massachusetts General HospitalEffect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | 2027-08-30 |
Add all 60 to your calendar (.ics) → With an account.
Among the 1,029 studies in Osteoarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have osteoarthritis of the knee and at least one of the following conditions:
Exclusion Criteria:
Have had within 90 days prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive eloralintide subcutaneously (SC)
Drug: Eloralintide
Participants will receive placebo SC
Drug: Placebo
Participants will receive eloralintide SC
Drug: Eloralintide
Participants will receive placebo SC
Drug: Placebo
Administered SC
Also known as: LY3841136
Placebo administered SC
Percent Change from Baseline in Body Weight
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 64
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Change from Baseline in the WOMAC Pain Subscale Score
Time frame: Baseline, Week 64
Change from Baseline in Systolic Blood Pressure (SBP)
Change from Baseline in SBP
Time frame: Baseline, Week 64
Percent Change from Baseline in Triglycerides
Percent Change in Baseline in Triglycerides
Time frame: Baseline, Week 64
Change from Baseline in Short Form-36 (SF-36 v2) Acute Form Physical Functioning Domain Score
Change from Baseline in SF-36 v2 Score
Time frame: Baseline, Week 64
Percent Change from Baseline in High Sensitivity, C-reactive Protein (hsCRP)
Percent Change from Baseline in hsCRP
Time frame: Baseline, Week 64
Change from Baseline in the WOMAC Physical Function Subscale Score
Change from Baseline in the WOMAC Physical Function Subscale Score
Time frame: Baseline, Week 40, Week 64
Change from Baseline WOMAC Pain Subscale Score
Change from Baseline WOMAC Pain Subscale Score
Time frame: Baseline, Week 40
Change from Baseline in Distance Walked During the 6-Minute Walk Test
Change from Baseline in Distance Walked During the 6-Minute Walk Test
Time frame: Baseline, Week 64
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in BMI
Time frame: Baseline, Week 64
Change in Medication Use
Change in Medication Use
Time frame: Baseline, Week 64
Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score
Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score
Time frame: Baseline, Week 64
Change from Baseline in Health Status EQ-5D-5L Health State Utility
Change from Baseline in Health Status EQ-5D-5L Health State Utility
Time frame: Baseline, Week 64
Percent Change from Baseline in Fasting Insulin
Percent Change from Baseline in Fasting Insulin
Time frame: Baseline, Week 64
Percent Change from Baseline in Total Cholesterol
Percent Change from Baseline in Total Cholesterol
Time frame: Baseline, Week 64
Change from Baseline in Waist Circumference
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 64
Percent Change from Baseline in Hemoglobin A1c (HbA1c)
Percent Change from Baseline in HbA1c
Time frame: Baseline, Week 64
Change from Baseline in WOMAC Stiffness Subscale Score
Change from Baseline in WOMAC Stiffness Subscale Score
Time frame: Baseline, Week 64
Change from Baseline in WOMAC Total Score
Change from Baseline in WOMAC Total Score
Time frame: Baseline, Week 64
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Pain
Achievement of Improved Categorical Shift in PGIS - Target Knee Pain
Time frame: Baseline, Week 64
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Function
Achievement of Improved Categorical Shift in PGIS - Target Knee Function
Time frame: Baseline, Week 64
Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score
Change from Baseline in API-NRS Score
Time frame: Baseline, Week 64
Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS) Score
Change from Baseline in WPI-NRS Score
Time frame: Baseline, Week 64
Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax, ss)
PK: Cmax, ss
Time frame: Baseline through Week 64
PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-T)ss)
PK: AUC(0-T)ss
Time frame: Baseline through Week 64
Number of Participants with Allowed Concomitant Pain Medication
Number of Participants with Allowed Concomitant Pain Medication
Time frame: Baseline, Week 64
Showing the first 100 of 147 sites across 13 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.
Of 60 industry-sponsored phase 3 interventional studies under Osteoarthritis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's planned 25 months is above that.
Counting every sponsor, half of 84 studies reached it within 17 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eloralintide